KPV
Also known as: Lysine-Proline-Valine (alpha-MSH 11-13)
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), corresponding to residues 11-13. It is the smallest alpha-MSH fragment shown to retain anti-inflammatory activity. Research-only; not FDA-approved; evidence is primarily preclinical.
Pricing for KPV
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for KPV
73 third-party tests across 20 vendors. Each card links to the full report.
For
KPV
by Crush Research· batch CR-KPV-10-2605-1
For
KPV
by Moglabs· batch KPV002
For
KPV
by EZ Peptides· batch EZP-KPV1005152026-12
For
KPV
by Nox Amino· batch NA-KP0526-01
For
KPV
by NG Peptide· batch KP10-05
For
KPV
by Glacier Aminos· batch KPV10GA-03
For
KPV
by Real Peptides· batch Black Cap
For
KPV
by Crush Research· batch CRKPV-10-2604-1
For
KPV
by Riptide Wellness· batch RWKPV-10-1003
For
KPV
by Sunrise Bioresearch· batch KPV10APR2026
For
KPV
by OROS Research· batch OR-LPKPV15-426-B2
For
KPV
by Peptide Plugs· batch 112-U-A
For
KPV
by Verified Peptides· batch cmp4wgc1s004px7rxyjbwbykv
For
KPV
by Amino Club· batch KPV0001
For
KPV
by Crush Research· batch CR-KPV10-2603-1
For
KPV
by Crush Research· batch CR-KPV10-2603-1
For
KPV
by IDUN Peptides· batch KV10-260318
For
KPV
by Glacier Aminos· batch KPV10GA-03
For
KPV
by Licensed Peptides· batch KPV-XXX-01
For
KPV
by Amino Club· batch KP1120
For
KPV
by BioLongevity Labs· batch 64-3-46031
For
KPV
by Peptide Partners· batch KV202601
For
KPV
by Mile High Compounds· batch KPV-010-MH-02
For
KPV
by Skye Peptides· batch KPV26-10-001
13 citations indexed for KPV
Study · 2026
Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells
Hepatocellular steatosis, an early stage within the non-alcoholic fatty liver disease (NAFLD) spectrum, is characterized by excessive lipid accumulation and oxidative stress in hepatocytes.
Study · 2026
Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers
Oral delivery of peptide therapeutics remains challenging due to gastrointestinal (GI) degradation and poor intestinal absorption.
Study · 2026
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of anabolic-androgenic steroids (AAS) to novel agents such as peptides and peptide analogues.
Study · 2026
NLRP3 autophagic degradation disruption in melanocytes contributes to vitiligo development
NLRP3 functions as a critical intracellular danger sensor for inflammasome activation, playing a crucial role in autoimmune diseases. Vitiligo progression has been linked to NLRP3, yet its specific involvement in melanocytes of vitiligo remains poorly understood.
review · 2026
Mechanistic studies of hydrogels in oral cancer treatment: Synergistic effects of drug delivery and immune modulation
Oral cancer ranks among the most prevalent malignant tumors of the head and neck, comprising 1%-2% of all global malignancies.
review · 2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.